Gerresheimer (XTRA:GXI) Valuation in Focus After Net Loss and Guidance Cut for 2025

Gerresheimer (XTRA:GXI) shares are in focus after the company reported a net loss for the third quarter and the first nine months of 2025. The company also provided updated guidance that points to an expected organic revenue decline for the year.

See our latest analysis for Gerresheimer.

Gerresheimer shares have struggled this year, with the stock dropping sharply. Recent earnings and the cut to annual guidance have not helped, fueling a wave of negative sentiment among investors. The 1-year total shareholder return stands at –64.5%, and momentum has clearly faded as management contends with both operational headwinds and shifting market expectations.

If recent events have you looking for new growth stories outside pharma suppliers, now is a great time to broaden your search and discover fast growing stocks with high insider ownership

With shares trading at a steep discount to analyst targets and confidence shaken after weak results, investors are left to consider whether Gerresheimer is now undervalued or if the market already reflects its growth challenges ahead.

Most Popular Narrative: 54.9% Undervalued

Gerresheimer's fair value is pegged at €63.72 in the most followed narrative, which is more than double its latest close of €28.76. This price gap sets the stage for an intriguing growth opportunity, according to the narrative’s underlying assumptions and catalysts.

The acquisition of Bormioli Pharma is expected to propel Gerresheimer's revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company's adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.

Read the complete narrative.

What’s driving this bold value call? The secret sauce is a unique blend of aggressive profit margin moves, ramped-up new production, and a strategic transformation that is typically seen in industry disruptors. Ready to find out if these ambitious assumptions justify such a dramatic upside?

Result: Fair Value of €63.72 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, integration risks from the Bormioli Pharma acquisition and seasonal cash flow fluctuations could introduce further uncertainty for Gerresheimer’s optimistic narrative.

Find out about the key risks to this Gerresheimer narrative.

Build Your Own Gerresheimer Narrative

If you would rather follow your own instincts or dig into the numbers directly, you can shape a personal Gerresheimer outlook in just a few minutes. Do it your way

A great starting point for your Gerresheimer research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Make your next move count by spotting unique opportunities before the crowd does. Don't let the smartest stock picks slip away from your radar.

• Capitalize on robust payouts and unlock rewarding returns from these 19 dividend stocks with yields > 3% offering yields above 3% to power your portfolio's income potential.
• Ride the next wave of digital finance innovation by tapping into these 79 cryptocurrency and blockchain stocks that are pioneering crypto-enabled payments and blockchain breakthroughs.
• Get ahead in the AI revolution as you check out these 24 AI penny stocks fueling growth with transformative machine learning and automation technologies.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com